These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11811386)

  • 21. Patient reperfusion preferences in acute myocardial infarction: mortality versus stroke, benefits versus costs, high technology versus drugs.
    Tsui W; Pierre K; Massel D
    Can J Cardiol; 2005 Apr; 21(5):423-31. PubMed ID: 15861260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase in neutrophils after recombinant tissue plasminogen activator thrombolysis predicts poor functional outcome of ischaemic stroke: a longitudinal study.
    Shi J; Peng H; You S; Liu Y; Xu J; Xu Y; Liu H; Shi R; Cao Y; Liu CF
    Eur J Neurol; 2018 Apr; 25(4):687-e45. PubMed ID: 29341345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finding new drugs to treat stroke.
    Barinaga M
    Science; 1996 May; 272(5262):664-6. PubMed ID: 8614822
    [No Abstract]   [Full Text] [Related]  

  • 24. Role of tissue plasminogen activator in acute ischemic stroke.
    Hatcher MA; Starr JA
    Ann Pharmacother; 2011 Mar; 45(3):364-71. PubMed ID: 21386027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis.
    Dorado L; Millán M; de la Ossa NP; Guerrero C; Gomis M; López-Cancio E; Ricciardi AC; Dávalos A
    Eur J Neurol; 2010 Feb; 17(2):301-6. PubMed ID: 19912320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
    Prescrire Int; 2005 Aug; 14(78):146-52. PubMed ID: 16106599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).
    Eissa A; Krass I; Bajorek BV
    J Clin Pharm Ther; 2012 Dec; 37(6):620-9. PubMed ID: 22708668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thrombolysis in Real Time: Demonstration of Revascularization with Intravenous Thrombolysis Therapy in the CT Scanner.
    Tan J; Aysenne A; Singh V
    J Neuroimaging; 2017 Jan; 27(1):50-58. PubMed ID: 27653945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombolysis.
    Lees KR
    Br Med Bull; 2000; 56(2):389-400. PubMed ID: 11092088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reperfusion after 4.5 hours reduces infarct growth and improves clinical outcomes.
    Picanço MR; Christensen S; Campbell BC; Churilov L; Parsons MW; Desmond PM; Barber PA; Levi CR; Bladin CF; Donnan GA; Davis SM;
    Int J Stroke; 2014 Apr; 9(3):266-9. PubMed ID: 24256139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal timing of thrombolytic therapy in acute ischaemic stroke.
    Madden K
    CNS Drugs; 2002; 16(4):213-8. PubMed ID: 11945105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocardial infarction. ESCALAT Investigators.
    Fung AY; Lorch G; Cambier PA; Hansen D; Titus BG; Martin JS; Lee JJ; Every NR; Hallstrom AP; Stock-Novack D; Scherer J; Weaver WD
    Am Heart J; 1999 Oct; 138(4 Pt 1):696-704. PubMed ID: 10502216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.
    Zamanlu M; Farhoudi M; Eskandani M; Mahmoudi J; Barar J; Rafi M; Omidi Y
    J Drug Target; 2018 Feb; 26(2):95-109. PubMed ID: 28796540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombolysis in acute cerebrovascular disease: indications and limitations.
    Hacke W; Ringleb P; Stingele R
    Thromb Haemost; 1999 Aug; 82(2):983-6. PubMed ID: 10605813
    [No Abstract]   [Full Text] [Related]  

  • 35. Thrombolytic stroke therapy: past, present, and future.
    Zivin JA
    Neurology; 1999 Jul; 53(1):14-9. PubMed ID: 10408530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombolytic therapy for acute ischemic stroke: 3 h and beyond.
    Padma V; Fisher M; Moonis M
    Expert Rev Neurother; 2005 Mar; 5(2):223-33. PubMed ID: 15853492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update.
    Derex L; Nighoghossian N
    J Neurol Neurosurg Psychiatry; 2008 Oct; 79(10):1093-9. PubMed ID: 18223014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thrombolysis and neuroprotection in cerebral ischemia.
    Gutiérrez M; Díez Tejedor E; Alonso de Leciñana M; Fuentes B; Carceller F; Roda JM
    Cerebrovasc Dis; 2006; 21 Suppl 2():118-26. PubMed ID: 16651822
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined full-dose IV and endovascular thrombolysis in acute ischaemic stroke.
    Bhatia R; Shobha N; Menon BK; Bal SP; Kochar P; Palumbo V; Wong JH; Morrish WF; Hudon ME; Hu W; Coutts SB; Barber PA; Watson T; Goyal M; Demchuk AM; Hill MD
    Int J Stroke; 2014 Dec; 9(8):974-9. PubMed ID: 23013039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.